Ophthalmic Plastic and Reconstructive Surgery最新文献

{"title":"Re: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease.","authors":"Itay Nitzan, Zvi Gur","doi":"10.1097/IOP.0000000000003248","DOIUrl":"10.1097/IOP.0000000000003248","url":null,"abstract":"","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e254"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148536557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply re: A Comprehensive Review of Dacryoscintigraphy: Part I-Indication, Techniques, and Utility.","authors":"Hatem A Tawfik, Bhupendra C Patel, Raman Malhotra, Mohammad Javed Ali","doi":"10.1097/IOP.0000000000003280","DOIUrl":"10.1097/IOP.0000000000003280","url":null,"abstract":"","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e255-e256"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periorbital Necrotizing Sweet Syndrome: A Case Report and Literature Review.","authors":"Henry Bair, Narmien Murdock, Lara Cheslow, Julie S Kim, Alison Watson, Stacey M Gargano, Kenneth Morgenstern, Michael P Rabinowitz","doi":"10.1097/IOP.0000000000003171","DOIUrl":"10.1097/IOP.0000000000003171","url":null,"abstract":"<p><p>Necrotizing periorbital Sweet syndrome is an uncommon mimic of necrotizing fasciitis that requires contrasting management. We describe a 60-year-old man with rapidly progressive unilateral eyelid edema, pain, and necrosis unresponsive to broad-spectrum antibiotics. Computed tomography showed periorbital soft-tissue swelling with gas. Two debridements for presumed necrotizing fasciitis yielded \"dishwater\" fluid; histopathology and special stains revealed a dense neutrophilic dermatosis without organisms, and cultures grew only commensals. He improved promptly after high-dose corticosteroids. Hematologic evaluation for escalating leukocytosis uncovered acute myeloid leukemia with t (6;9) and neuroblastoma RAS viral oncogene homolog mutation. A targeted literature synthesis showed frequent initial misdiagnoses as cellulitis or necrotizing fasciitis, unnecessary debridement, common association with myeloid neoplasia, and rapid steroid response. Periorbital sweet syndrome should be considered when cultures are sterile and clinical status worsens despite antibiotics; early biopsy and empiric corticosteroids can avert morbidity and unmask occult malignancy.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e226-e231"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syringocystadenocarcinoma Papilliferum of the Eyelid: A Rare Case Report and Review of the Literature.","authors":"Lily C Farrell, Carol L Shields, Anna M Stagner, Tatyana Milman","doi":"10.1097/IOP.0000000000003152","DOIUrl":"10.1097/IOP.0000000000003152","url":null,"abstract":"<p><p>Syringocystadenocarcinoma papilliferum is an exceptionally rare malignant adnexal neoplasm of sweat gland origin, with fewer than 90 cases reported in the literature, most arising within the head and neck region. Periocular involvement is exceedingly uncommon, with only 3 previously documented cases, one of which was confined to the eyelid. The authors describe an 80-year-old man who presented with new onset erythema, irritation, and growth of a long-standing upper eyelid lesion. Incisional biopsy was interpreted as squamous cell carcinoma with papillary morphology. Subsequent excision and histopathologic examination of the entire lesion led to a diagnosis of syringocystadenocarcinoma papilliferum arising in a background of syringocystadenoma papilliferum. This case adds to the limited literature of syringocystadenocarcinoma papilliferum in the periocular region, highlighting the clinical presentation, pathologic features, and biologic behavior of this rare tumor in the ocular adnexa.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e202-e205"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145794409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Industry Payments Among Oculofacial Plastic Surgeons: An Open Payments Database Analysis.","authors":"Keegan B Mechels, Katerina Tori, Hudson Pangan, Lillian Art, Hui Bae Harold Lee","doi":"10.1097/IOP.0000000000003161","DOIUrl":"10.1097/IOP.0000000000003161","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the distribution of payments made to oculofacial plastic surgeons who are members of the American Society of Ophthalmic Plastic and Reconstructive Surgeons, and examine the regularity of financial relationships between industries and oculofacial plastic surgeons.</p><p><strong>Methods: </strong>This analysis included all American Society of Ophthalmic Plastic and Reconstructive Surgeons fellow members listed in the online directory. Annual statistical data were obtained from the Open Payments Database, and all general payments distributed to oculoplastic surgeons were recorded. Data are summarized by company and amounts distributed to the member. The main outcome is the cumulative payments made by the highest 3 individual industry companies to oculoplastic surgeons using data available from 2021 to 2023. Secondary outcomes looked at payments to leadership positions within the American Society of Ophthalmic Plastic and Reconstructive Surgeons.</p><p><strong>Results: </strong>Six hundred twenty-seven surgeons received $13,069,190.03 over 6,831 payments. The average payment was $1,913.22, while the median payment was $117.12. The top 10 companies contributed a total of $11,540,952.07 (88.3%) of payments while the top 20 surgeons were paid $9,210,203.88 (70.5%) of all contributions. The top 3 companies contributed $9,088,333.48 (69.5%) of payments. In the $10,000 to $99,999 category, Horizon contributed $2,145,840.48 to 69 surgeons, while Galderma and Allergan contributed $113,355.12 to 3 surgeons and $298,972.96 to 11 surgeons, respectively. Between $1,000 and $9,999, Horizon made payments totaling $298,331.84 to 80 surgeons, Galderma contributed $24,289.64 to 7 surgeons, and Allergan contributed $72,768.35 to 27 surgeons. Fifty-six program directors took part in training fellows in oculofacial plastic surgery. The total payment volume for odd-year programs was $2,549,997.64 with an average of $87,930.95 and median of $6,841.28. The total for even-year programs was $1,511,807.29 with an average and a median of $55,992.86 and $1,326.70, respectively. Thirty-three members of the American Society of Ophthalmic Plastic and Reconstructive Surgeons' current or past 10-year executive committee/board of directors were paid $3,975,434.02, with an average payment of $120,467.70 and a median payment of $3,706.88.</p><p><strong>Conclusions: </strong>The reporting of open payments to providers is important in providing transparency between physicians and industry. There exists a great discrepancy in the distribution of industry payment within oculofacial plastics, showing a very strong apical dominance with relatively few surgeons receiving a higher number of payments, larger total reimbursements, and from relatively few companies.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"529-533"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Ocular Adnexal Lymphoma: Past, Present, and Future.","authors":"Kelsey L Walsh, Matthew H McCartney, Christopher J Fraser, Timothy J Sullivan","doi":"10.1097/IOP.0000000000003176","DOIUrl":"10.1097/IOP.0000000000003176","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize the clinical, imaging, and pathological spectrum of pediatric ocular adnexal lymphomas tumors (OAL), including both primary and secondary lesions, using contemporary World Health Organization Haematolymphoid (5th edition) classification.</p><p><strong>Methods: </strong>This retrospective case series included patients <18 years with biopsy-proven lymphoma of the orbit or ocular adnexa managed by a single oculoplastic surgeon over a 30-year period. Demographic, clinical, imaging, histopathological, treatment, and outcome data were collected. Lesions were categorized as primary (confined to ocular adnexa with or without regional lymph nodes) or secondary (ocular adnexa involved as part of systemic lymphoproliferative disease).</p><p><strong>Results: </strong>Eleven patients (median age 11 years; 6 male) were identified. Five (45%) had precursor B-cell lymphoblastic leukemia/lymphoma, and 3 (27%) had mature B-cell tumors, including 2 extranodal marginal zone lymphomas and 1 diffuse large B-cell lymphoma. Three (27%) had mature natural killer/T-cell neoplasms, including 1 primary cutaneous anaplastic large cell lymphoma, 1 anaplastic large cell lymphoma, and 1 extranodal natural killer/T-cell lymphoma, nasal type. Six patients (55%) presented with ocular adnexal involvement secondary to systemic disease, most commonly in the orbit. Periorbital swelling, proptosis, and palpable masses were the predominant ocular signs. Management ranged from surgical excision or topical interferon to systemic chemotherapy, radiotherapy, and hematopoietic stem-cell transplantation. At the last follow-up, outcomes varied with histological subtype and disease stage.</p><p><strong>Conclusions: </strong>Pediatric ocular adnexal lymphomas displays striking clinicopathologic heterogeneity, with a predominance of precursor lymphoblastic neoplasms and a notable proportion of high-grade mature B- and T/NK-cell lymphomas. Recognizing both primary and secondary lesions and applying accurate histopathological classification are critical for timely diagnosis and to guide modern targeted therapies. This series expands the evidence base for a rare disease and underscores the importance of integrating ophthalmic assessment with contemporary World Health Organization diagnostic frameworks.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"512-522"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upper Eyelid Retraction: An Atypical Sign of Orbital Conjunctival Inclusion Cyst.","authors":"Aline Ramos da Silva, Renata Fernandes Cunha, Fernando Chahud, Antonio Augusto Velasco E Cruz","doi":"10.1097/IOP.0000000000003180","DOIUrl":"10.1097/IOP.0000000000003180","url":null,"abstract":"<p><p>Orbital conjunctival inclusion cysts are uncommon lesions that may develop as congenital choristomatous rests or as a result of traumatic or iatrogenic implantation of conjunctival epithelium. Depending on their size and location, they can be asymptomatic or cause proptosis, diplopia, mechanical ptosis, and ocular motility disturbances. We report a rare case of a 63-year-old female patient who developed marked upper eyelid retraction due to a conjunctival inclusion cyst associated with a retinal detachment procedure performed 20 years before presentation. A literature review did not disclose any case of upper eyelid retraction associated with orbital conjunctival inclusion cysts.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e238-e241"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orbital Cellular Myofibroma: A Rare Case With Detailed Vascular Characterization.","authors":"Sonia Anchouche, Kenneth Chang, Mohammad Altibi, Brendan C Dickson, Pascal J Mosimann, Dan D DeAngelis","doi":"10.1097/IOP.0000000000003199","DOIUrl":"10.1097/IOP.0000000000003199","url":null,"abstract":"<p><p>This case report describes a rare presentation of orbital cellular myofibroma in a 30-year-old female who initially presented with right proptosis and conjunctival injection. Endovascular embolization followed by surgical resection revealed an unencapsulated, vascular tumor with histopathologic and molecular findings consistent with cellular myofibroma harboring an SRF::RELA gene fusion. This case highlights the diagnostic challenges associated with orbital tumors and the importance of considering myofibroma in the differential diagnosis. The report also underscores the role of multidisciplinary management in optimizing outcomes for patients with rare orbital neoplasms.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e247-e250"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Subcutaneous Tranexamic Acid on Hemostasis and Ecchymosis in Oculofacial Procedures: A Double-Blind, Placebo-Controlled, Randomized Trial.","authors":"Wenyu Deng, Michael Kozlov, Roman Shinder","doi":"10.1097/IOP.0000000000003194","DOIUrl":"10.1097/IOP.0000000000003194","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to assess the hemostatic effect of local tranexamic acid (TXA) in varied oculofacial procedures.</p><p><strong>Methods: </strong>This is a prospective, randomized, placebo-controlled, double-blind study of 3,234 consecutive patients undergoing oculofacial procedures by a single surgeon (RS) between July 2020 and July 2024. Institutional review board approval was obtained. Patients undergoing unilateral procedures were randomized to either receive local anesthesia with or without TXA, with a concentration of 10 mg TXA/1 ml local anesthetic. For bilateral procedures (e.g., upper blepharoplasty), patients were randomized to receive local TXA solution in 1 eyelid while the contralateral lid received a placebo. Cautery was used in upper blepharoplasty, dacryocystorhinostomy, and lacrimal gland biopsy. Primary outcomes of the study included the duration of surgery, duration of cautery for specific procedures, degree of ecchymosis on postoperative day 7, and days until ecchymosis resolved.</p><p><strong>Results: </strong>Treatment groups for all procedures were similar in terms of gender, age, medical history, and ultimate histopathologic diagnosis when biopsy was performed. Duration of cautery and surgery, ecchymosis grade on postoperative day 7, and duration to ecchymosis resolution were all significantly decreased for the patients treated with TXA for all surgical procedures. No complications, including thromboembolic events, were noted in the TXA group.</p><p><strong>Conclusion: </strong>TXA in local anesthetic proved safe and effective at reducing bleeding, surgical time, and ecchymosis at postoperative day 7, with a shorter overall duration of ecchymosis in this cohort.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"559-563"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Periorbital Extra-skeletal Osteoma: A Novel Clinical Entity.","authors":"Azraa S Chaudhury, Celestine H Gregerson, Melissa Li, Nicole Maddie, Kyle J Godfrey","doi":"10.1097/IOP.0000000000003153","DOIUrl":"10.1097/IOP.0000000000003153","url":null,"abstract":"<p><p>Osteomas are typically slow-growing benign masses that do not require surgical intervention unless the patient is symptomatic. Orbital osteomas are rare, with fewer than 15 cases of primary orbital osteomas documented in the literature. When present, an osseous connection to the bony orbit is usually noted. The authors present the first report of a primary periorbital extra-skeletal osteoma.</p>","PeriodicalId":19588,"journal":{"name":"Ophthalmic Plastic and Reconstructive Surgery","volume":" ","pages":"e205-e208"},"PeriodicalIF":1.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146207296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}